BAFF and its receptors:contribution and therapeutic potential in atherosclerosis

BAFF及其受体：在动脉粥样硬化中的贡献和治疗潜力

• 批准号: nhmrc : 1025211
• 负责人: A/Pr Peter Tipping
• 金额: $ 37.52万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/baff-receptorscontribution-therapeutic-potential-atherosclerosis/110417
• 关键词: BAFF; its; receptors; contribution; therapeutic

Atherosclerosis is an inflammatory reaction to cholesterol in blood vessels. Despite cholesterol-lowering statins, atherosclerosis-based heart attacks and strokes remain a major cause of deaths. Studies of BAFF, a pro-inflammatory molecule can shed new light on the inflammation. As BAFF blockers are already in clinical trials to treat inflammatory diseases, our study has potential to lead to using BAFF blockers to treat human atherosclerosis.

动脉粥样硬化是对血管中胆固醇的炎症反应。尽管他汀类药物可以降低胆固醇，但基于动脉粥样硬化的心脏病发作和中风仍然是死亡的主要原因。对促炎症分子BAFF的研究可以为炎症提供新的线索。由于BAFF阻滞剂已经处于治疗炎症性疾病的临床试验中，我们的研究有可能导致使用BAFF阻滞剂治疗人类动脉粥样硬化。